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Authors' reply
Dear editor
We wish to thank Dr Kenessey for his queries and offer the following responses to help clarify the issues raised.
Regarding the use of the two source databases, the manuscript went through multiple rounds of revisions and was peer-reviewed by five reviewers (including the earlier version of the manuscript) and two editors. At no stage were any concerns raised about the clarity of data sources, because it was clarified in the article, as quoted "Population-based incidence data for the period between 2001 and 2014 were collected by the National Cancer Registry of Hungary. Mortality data for the time frame between 1996 and 2015 were acquired from the Central Statistical Office of Hungary. The National Cancer Registry of Hungary was established in 2000 to replace former hospital-based data collection systems, and it remains in close contact with community hospitals to ensure the quality of the compiled data. Since 2001, the collected incidence data are publicly available". Since there is only a single National Cancer Registry of Hungary, there was no place for any ambiguity as to the database used. More importantly, although the database of the National Cancer Registry is a publicly available website, all the data are listed in Hungarian only and there is no English translation available. We did not think providing the link to this site would be very beneficial for the international readers who comprise the majority of Clinical Epidemiology's readership.
In response to the selection criteria, the number one ranked journal in the field of Oncology (CA: A Cancer Journal for Clinicians) publishes the yearly US Cancer Statistics in which "All cancer cases are classified according to the International Statistical Classification of Diseases and Related Health Problems, 10th revision". We used the same classification system for our selection criteria as was detailed in the article. As the data were downloaded from the National Cancer Registry of Hungary, the database does not contain information about secondary malignancies (C77-C79) and therefore could not have been included in the analysis. We followed the common international practice in which C44 is not included in the group of melanomas of the skin. In our tables, the major types of malignancies were clearly labeled, and the manuscript included the statistics of the major cancer types.
Regarding the issue raised about the number of patients reported as dying due to malignant disease, we downloaded all mortality data on the 16th of September 2016. In the mortality data, we included all cases listed under C00-D48, including benign tumors and tumors with ambiguous origin. If these tumors were left out, the numbers would correspond with the number presented by Dr Kenessey. Our justification for the inclusion of this data was that these tumors were indeed lethal and our intention was to provide the most comprehensive tumor-related characterization of the present mortality in the population.
In response to the incidence and mortality analyses, we clearly indicated in the manuscript the sources of the incidence and mortality data, and how data availability restricts this analysis. For estimates of overall mortality, we refer to our previous response. The future estimates for incidence and mortality of each tumor type strictly depends on the specific data for that tumor. For example, female breast cancer (BC) is labeled by the BNO code, C50. Thus, both incidence and mortality estimates for BC were only based on C50 data. It would be beneficial for the National Cancer Registry to change its practice and harmonize the list of collected data with the Central Statistical Office of Hungary for the sake of better compatibility.
Finally, according to a statement on the website of the National Cancer Registry, the most recent data are not publicly available, because of ongoing quality controls, and "data for the latest 3-5 years are likely to change after finishing the corrections". We downloaded the data in the Fall of 2016, when data from 2015 were not yet available. This is why we substituted data from 2015 with the mean of the two most recent years, as described in the Methods section. Minor discrepancies between our case numbers and that of the reader can be expected due to recent data corrections.
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